ライフサイエンスコーパス: pain control

1 (cases) and 348 individuals with no chronic pain (controls).

2 ally scripted patient-physician dialog about pain control.

3 oles of NAAG, that promise rapid advances in pain control.

4 part because of patient-related barriers to pain control.

5 g the shift to end-of-life care and adequate pain control.

6 tter with M+H, in particular with respect to pain control.

7 ces of misuse of opioid drugs prescribed for pain control.

8 erious obstacle to the provision of adequate pain control.

9 hould be tried before starting narcotics for pain control.

10 37]) were better than placebo for short-term pain control.

11 sign, increasing the focus on postoperative pain control.

12 ggesting a spatial specificity of endogenous pain control.

13 P10 participate in Kv4.3-mediated mechanical pain control.

14 y, and are excellent therapeutic targets for pain control.

15 of increasing the duration of postoperative pain control.

16 treatment groups did not use analgesics for pain control.

17 e of this structure for sleep regulation and pain control.

18 al management center of sleep regulation and pain control.

19 e its potential significance for therapeutic pain control.

20 e pharmacological target for female-specific pain control.

21 f prodynorphin and other downstream genes in pain control.

22 he spinal cord may be involved in endogenous pain control.

23 eric pumps, is recommended for postoperative pain control.

24 sedative regimen that did not include opiate pain control.

25 on, the avoidance of opioids, and aggressive pain control.

26 ious difficulties for the use of opioids for pain control.

27 nts provide similar responses to amnesia and pain control.

28 commonly used to provide acute postoperative pain control after major surgery.

29 esia may be superior to opioids for improved pain control along with increased patient satisfaction a

30 lower reported income; dissatisfaction with pain control also varied among study hospitals and by ph

31 Pain control among hospitalized patients is a national p

32 act infections, 3 (0.3%) readmissions (2 for pain control and 1 for mild confusion that resolved with

33 ductal gray (PAG), a structure important for pain control and learning in animal models.

34 superior patient experience through improved pain control and less narcotic use, without increased le

35 Analgesic techniques that provide optimal pain control and low side effect profiles with minimal o

36 Its use is essential in improving patient pain control and overall satisfaction as well as decreas

37 disease benefits patients in terms of better pain control and preservation of pancreatic function.

38 y recurrent rectal cancer (LRRC) is limited, pain control and quality of life (QOL) are important par

39 and reassurance regarding issues of safety, pain control and respect for patient preferences are imp

40 d improve patient-centered outcomes, such as pain control and satisfaction.

41 We assessed data for pain control and skeletal-related events prospectively c

42 at minority patients do not receive adequate pain control and that better assessment of pain is neede

43 e, that the EP3 receptor provides endogenous pain control and that selective activation of EP3 recept

44 stopped or used no opioids owing to adequate pain control, and 16% to 29% of patients reported opioid

45 aster improvement in corneal clarity, better pain control, and avoidance of surgery in an inflamed ey

46 Bowel rest, pain control, and intravenous fluids are the cornerstone

47 ence of skeletal-related events, measures of pain control, and patient-reported health-related qualit

48 n, minimization of organ dysfunction, active pain control, and promotion of patient autonomy).

49 otential to enhance quality of life, improve pain control, and reduce suffering for patients with can

50 ents, discovery of better anesthetic agents, pain control, and the evolution of perioperative care ar

51 onds to a conservative regimen of hydration, pain control, and the temporary discontinuation of the m

52 articularly colloid administration, adequate pain control, and treatment of pulmonary hypertension, m

53 herapy; a lack of evidence-based research on pain control; and misconceptions and prejudices about dr

54 ids, aerosolized beta agonists, and adequate pain control are necessary to reduce morbidity.

55 st a new, dramatically different approach to pain control, as all clinical therapies are focused excl

56 d membrane stabilizing analgesics as well as pain control at the genetic level are discussed.

57 erapy, since it was associated with a modest pain control benefit in controlled trials.

58 Epidurals may be associated with superior pain control but this does not translate into improved r

59 blished intervention for ventral hernia, but pain control can be challenging.

60 nd other relevant outcome domains, including pain control, cardiac complications, and overall recover

61 ediated, noxious stimulus-induced endogenous pain control circuit.

62 yndromes can modulate activity in endogenous pain control circuits and that this effect is sympathoad

63 syndromes on the function of the endogenous pain control circuits at which these drugs act to produc

64 The main outcome measure was pain control combined with change of toxicity, as measur

65 g) with hydrocodone (5 mg) results in better pain control compared to ibuprofen used alone.

66 t delivered to patients, and the "subjective pain control" condition, during which the intensity of s

67 thologic fracture, radiation for fracture or pain control, conservatively treated pathologic fracture

68 nomy (91.6%) and dignity (78.7%); inadequate pain control contributed in 25.2% of cases.

69 Pain control, delirium, and pressure ulcer prevention ar

70 e from the use of a snail toxin to develop a pain control drug, metabolites from a sea squirt to deve

71 Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but

72 ed as an adjunct procedure for postoperative pain control during elective abdominal aortic aneurysm (

73 t and process of care factors that influence pain control during FOB.

74 s patient global assessment of the method of pain control during the first 24 hours.

75 is to deliver fentanyl provided postsurgical pain control equivalent to that of a standard intravenou

76 Addressing pain control expectations before discharge may help redu

77 nd thermosetting agents may be effective for pain control for scaling and root planing and may offer

78 discontinuation rate for lack of acceptable pain control (from 34% to 4% with CR and from 31% to 19%

79 ell as changes in quality of life, perceived pain control, functional status, analgesics, and physici

80 Acute pain control has advanced dramatically and is now a fiel

81 ion of economic and humanitarian benefits of pain control has prompted worldwide attention from profe

82 els, with relevance to mechanisms underlying pain control, hypertension and anxiety.

83 With increased emphasis on pain control in children, it is likely that iatrogenic w

84 ous bisphosphonate, pamidronate disodium, on pain control in metastatic prostate cancer patients.

85 eutic approaches have substantially improved pain control in past years.

86 Thus, research and training on pain control in sickle cell disease are needed to parall

87 Conservative debridement of necrotic bone, pain control, infection management, use of antimicrobial

88 management of lines, tubes, and drains, and pain control interventions.

89 order, anesthesia type, first or second eye, pain control, intra-operative heart rate and blood press

90 Although adequate postoperative pain control is critical to patient and surgeon success,

91 kers have demonstrated that this approach to pain control is feasible.

92 Pain control is of uttermost importance and stimulus con

93 The clinical efficacy of opiates for pain control is severely limited by analgesic tolerance

94 ing corticosteroids to stronger opioids when pain control is the primary objective.

95 t whether they participate in Kv4.3-mediated pain control is unknown.

96 tinues for as long as the opiate is used for pain control, is constipation.

97 Optimal pain control may improve quality of life (QOL) for these

98 l advance in the understanding of endogenous pain control mechanisms by bridging the gap between prev

99 Endogenous pain control mechanisms have long been known to produce

100 In particular, endogenous pain control mechanisms, such as stress-induced analgesi

101 rating theatre and anaesthetic technique and pain-control methods were standardised.

102 ensuring a calming environment and adequate pain control, minimizing benzodiazepines and anticholine

103 laparoscopy appears to improve postoperative pain control modestly, especially when given into the pe

104 n directed to supportive care including oral pain control, nutritional support, infection treatment a

105 use of an easy, inexpensive, and achievable pain control option.

106 or second eye surgery affect intra-operative pain control or are correlated with type of anesthesia m

107 on did not affect quality of life, perceived pain control, or functional status.

108 as a possible benefit of M+H with respect to pain control over hydrocortisone alone.

109 us patient-controlled analgesia (IV-PCA) for pain control over the first 48 hours after hepatopancrea

110 prove adherence and, ultimately, to optimize pain control over time.

111 tion (anterior cingulate cortex); descending pain control (periaqueductal grey); and an extensive net

112 ial tested the effectiveness of the PRO-SELF Pain Control Program compared with standard care in decr

113 IDDSs improved clinical success in pain control, reduced pain, significantly relieved commo

114 or dying nursing home residents by improving pain control, reducing hospitalization, and reducing use

115 tial patient-friendly therapeutic option for pain control related to inflammatory disorders of the TM

116 Pain control remained significantly improved after 36 mo

117 od than parenteral opioids for postoperative pain control remains controversial.

118 Interventions to improve pain control should consider modifying donor behavioral

119 This pain control strategy may help achieve dose escalation w

120 parate experiments directed at postoperative pain control, subcutaneous administration of RTX transie

121 us opioidergic circuits along the descending pain control system.

122 ip of level of pain and dissatisfaction with pain control to demographic, psychological, and illness-

123 Pain and satisfaction with pain control varied significantly among study sites, eve

124 Pain control was excellent in 36% of patients, but 10% c

125 In the 15-year long-term follow-up, the pain control was good and comparable between both groups

126 confounding variables, dissatisfaction with pain control was more likely among patients with more se

127 Patient factors associated with excellent pain control were excellent health (versus poor health,

128 fter 24 hours of treatment for the method of pain control were given by 73.7% of patients (233/316) w

129 ss of care factors associated with excellent pain control were not being bothered by scope insertion

130 s associated with pain and satisfaction with pain control were patient demographics and those variabl

131 act immune system plays an essential role in pain control, which is important for the understanding o

132 Efforts to fine tune pain control while alleviating the side effects of drugs

133 advent of additional vaccines, attention to pain control will take on increasing urgency.